Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

467

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Arthritis, Rheumatoid
Interventions
BIOLOGICAL

ABP 501

Solution for subcutaneous injection in a syringe containing 40 mg/0.8 mL ABP 501

Trial Locations (77)

1023

Research Site, Budapest

1027

Research Site, Budapest

1036

Research Site, Budapest

1612

Research Site, Soifia

4002

Research Site, Plovdiv

4003

Research Site, Plovdiv

6600

Research Site, Szentes

7012

Research Site, Rousse

8200

Research Site, Veszprém

8230

Research Site, Balatonfüred

11201

Research Site, Brooklyn

11501

Research Site, Mineola

15006

Research Site, A Coruña

15705

Research Site, Santiago de Compostela

16635

Research Site, Duncansville

18015

Research Site, Bethlehem

20902

Research Site, Wheaton

21740

Research Site, Hagerstown

22391

Research Site, Hamburg

28041

Research Site, Madrid

29406

Research Site, Charleston

30328

Research Site, Sandy Springs

32804

Research Site, Orlando

33015

Research Site, Miami

34233

Research Site, Sarasota

35801

Research Site, Huntsville

37075

Research Site, Göttingen

38119

Research Site, Memphis

40504

Research Site, Lexington

40882

Research Site, Ratingen

41009

Research Site, Seville

63141

Research Site, St Louis

68114

Research Site, Omaha

73103

Research Site, Oklahoma City

75007

Research Site, Carrollton

75231

Research Site, Dallas

85258

Research Site, Scottsdale

85381

Research Site, Peoria

90602

Research Site, Whittier

91405

Research Site, Van Nuys

91723

Research Site, Covina

92020

Research Site, El Cajon

92260

Research Site, Palm Desert

92543

Research Site, Hemet

99204

Research Site, Spokane

185019

Research Site, Petrozavodsk

810019

Research Site, Brăila

06810

Research Site, Danbury

R3N 0K6

Research Site, Winnipeg

A1A 5E8

Research Site, St. John's

N8X 5A6

Research Site, Windsor

128 50

Research Site, Prague

140 00

Research Site, Prague

Research Site, Prague

748 01

Research Site, Hlučín

702 00

Research Site, Ostrava

760 01

Research Site, Zlín

140 59

Research Site, Prague

04103

Research Site, Leipzig

64-000

Research Site, Kościan

60-218

Research Site, Poznan

61-113

Research Site, Poznan

85-168

Research Site, Bydgoszcz

87-100

Research Site, Torun

50-088

Research Site, Wroclaw

52-416

Research Site, Wroclaw

20-022

Research Site, Lublin

20-582

Research Site, Lublin

01-192

Research Site, Warsaw

01-518

Research Site, Warsaw

15-099

Research Site, Bialystok

15-351

Research Site, Bialystok

80-307

Research Site, Gdansk

81-338

Research Site, Gdynia

13-200

Research Site, Działdowo

82-300

Research Site, Elblag

IP33 2QZ

Research Site, Suffolk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02114931 - Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter